1. Patients launch $1.27 million crowdfunding campaign for ME/CFS gut microbiome study.
    Check out the website, Facebook and Twitter. Join in donate and spread the word!
Join the National PR Campaign for ME: Power to the Patient (P2tP)
Have you had enough of all the neglect and abuse of ME/CFS patients? Gabby Klein says now is the time for a National PR Campaign for ME/CFS to impress a change. Join the Patient Revolution to restore power to ME patients ...
Discuss the article on the Forums.

"Rituxan: re-energizing CFS", SciBX, 10/27/11

Discussion in 'Rituximab: News and Research' started by justinreilly, Nov 3, 2011.

  1. justinreilly

    justinreilly Stop the IoM & P2P! Adopt CCC!

    Messages:
    2,490
    Likes:
    1,175
    NYC (& RI)
    Anyone have access to the full article?


    http://www.nature.com/scibx/journal/v4/n42/full/scibx.2011.1167.html

    SciBX 4(42); doi:10.1038/scibx.2011.1167
    Published online Oct. 27 2011

    Rituxan: re-energizing CFS
    by Michael J. Haas, Senior Writer

    Even as XMRV has been taken off the table as a cause of chronic fatigue syndrome, new research from Norway points to the condition as a B cell disorder and suggests the potential to repurpose Rituxan and other CD20 antibodies for CFS.
     
  2. oceanblue

    oceanblue Senior Member

    Messages:
    1,174
    Likes:
    343
    UK
    Sorry, no, but I'd love to read it too. There seem to have been quite a lot of coverage of CFS in nature journals recently - even if the coverage hasn't been to everyone's liking I think it's very positive the illness is getting exposure in such serious science mags.
     
  3. shannah

    shannah Senior Member

    Messages:
    848
    Likes:
    179
    Dr. Enlander just posted some encouraging news on his FB page.

    "Dr David Bell and I will attempt to replicate the Rituximab study. David is enthusiastic in doing this as he retired from active practice and will come to New York to work with us in the new ME/CFS center."
     
    taniaaust1 likes this.
  4. Battery Muncher

    Battery Muncher Senior Member

    Messages:
    228
    Likes:
    256
    Sounds fantastic! Does anyone know who else is trying to replicate the Rituximab study?
     
  5. FancyMyBlood

    FancyMyBlood Senior Member

    Messages:
    175
    Likes:
    69
    I think you're already aware, but the Norwegians themselves will do a large, multicenter phase III RCT.
     
  6. SpecialK82

    SpecialK82 Senior Member

    Messages:
    897
    Likes:
    475
    USA
    Outstanding! I wonder if the patient pays? I don't see how the center could afford it unless they have funding....maybe they do...
     
  7. searcher

    searcher

    Messages:
    496
    Likes:
    1,243
    SF Bay Area
    My understanding is that Dr. Kogelnik in the SF Bay Area has been trying to set up a rituximab trial for some time. I am not sure where he is in the approval process.
     
  8. Sing

    Sing Senior Member

    Messages:
    1,362
    Likes:
    581
    New England
    Will Dr. Bell and Dr. Enlander being doing their study at the new Mount Sinai center, to which I just heard an ME patient has donated a million dollars?
     
  9. oceanblue

    oceanblue Senior Member

    Messages:
    1,174
    Likes:
    343
    UK
    Finally got to read this short Science-Business eXchange article by Michael Haas.

    It summarises the Fluge paper and looks at other commerical anti-CD20 monclonals that might have the same effect as rituximab (brand name Rituxan):
    Ofatumumab, from Genmab/GlaxoSmithKline is already on the market, licenced for different illnesses. There are 2 other mabs in development (Phase III trials for other illnesses), both from the same Biotech/Gentech/Roche consortium that produce rituximab: Ocrelizumab and GA101.

    What most interested me about the article was the additional information on the future planned studies by Mella and Fluge:

    1. Open-label maintenance trial of rituximab in 27 of 30 patients from the recent study (presumably excluding the 3 patients that recovered). I don't think we knew previously which patients were in the planned open-label study. Mella said:
    2. A phase II trial of rituximab in patients with severe CFS.

    3. Identification of an autoantibody marker for CFS, specifically ones that target nervous sensory proteins
    They intend to search for proteins that might compose such a filter by testing plasma from patients and healthy controls against known nervous system proteins from humans and animals.
     
    Firestormm and Kati like this.
  10. sensing progress

    sensing progress Senior Member

    Messages:
    296
    Likes:
    9
    Tucson, AZ
    thanks for posting the update on the article oceanblue!
     
  11. Sing

    Sing Senior Member

    Messages:
    1,362
    Likes:
    581
    New England
    These drug names begin to remind me of West and Central African names. I know this comment is irrelevant. Yet, I would be interested in reading an article on drug names by a linguistics pro. Any takers?
     
  12. sensing progress

    sensing progress Senior Member

    Messages:
    296
    Likes:
    9
    Tucson, AZ
    --------------
     
  13. Battery Muncher

    Battery Muncher Senior Member

    Messages:
    228
    Likes:
    256
    Good post Ocenblue! Will be interesting to see how the patients from the first trial fare on bigger doses (over longer period). I'm also delighted to hear Fluge and Mella's plans for finding autoantibody markers etc. Sounds like they have a good idea already!
     
  14. urbantravels

    urbantravels disjecta membra

    Messages:
    1,333
    Likes:
    507
    Los Angeles, CA
  15. Sing

    Sing Senior Member

    Messages:
    1,362
    Likes:
    581
    New England
    Thanks, urbantravels. I glanced at the journal link you offered. It looks as though this is an exciting realm for research now which is attracting a lot of interest and probably funding. Let's hope that our "mAb" works out!
     
  16. urbantravels

    urbantravels disjecta membra

    Messages:
    1,333
    Likes:
    507
    Los Angeles, CA
    One take-home message is that there is a whole menu of other mAbs (and still more being developed.) Rituximab looks promising for us right now; but there are also other options to try if Rituximab doesn't pan out for all patients.

    Rituximab just happens to be one of the mAbs that's been around longest and is one of the best-understood. (Yes, that includes possible side effects, some of them potentially very serious: but at least it's a 'devil you know' sort of situation - there's enough experience with the drug that they know what to watch out for, and in some cases can counteract the side effects.)
     

See more popular forum discussions.

Share This Page